コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ainst biomarkers, murine double minute 2 and platelet derived growth factor receptor.
2 r, insulin-like growth factor 1 receptor and platelet-derived growth factor receptor.
3 g epidermal growth factor receptor (EGFR) or platelet-derived growth factor receptor.
4 , including cellular inhibition of c-kit and platelet-derived growth factor receptor.
5 C/EBP-delta, superoxide dismutase 3, and the platelet-derived growth factor receptor.
6 eoglycan NG2, a co-receptor of integrins and platelet-derived growth factor receptor.
7 ity stimulated by epidermal growth factor or platelet-derived growth factor receptors.
8 in a national clinical trial suggested that platelet-derived growth factor receptor A (PDGFR-A) may
9 l tumors (GISTs) harboring activating KIT or platelet-derived growth factor receptor A (PDGFRA) mutat
10 gene), stem cell factor receptor (Kit), and platelet-derived growth factor receptor A and B (PDGFRA
11 tivation by a receptor activation loop (from platelet-derived growth factor receptor, a receptor tyro
13 r-defined signaling pathways, represented by platelet derived growth factor receptor alpha (PDGFRA) a
14 contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA),
17 Expression of the fusion gene FIP1-like 1/platelet-derived growth factor receptor alpha (FIP1L1/PD
18 ng hormone (LH) receptor (LHR)-negative, and platelet-derived growth factor receptor alpha (PDGFR alp
20 us in this mouse model is caused by aberrant platelet-derived growth factor receptor alpha (PDGFR-alp
22 e kinase activity by the Fip1-like1 (FIP1L1)-platelet-derived growth factor receptor alpha (PDGFRA) (
23 ification of two or more RTKs, most commonly platelet-derived growth factor receptor alpha (PDGFRA) a
24 GG), often in association with TP53 loss and platelet-derived growth factor receptor alpha (PDGFRA) a
25 Nkx2.2 can directly bind to the promoter of platelet-derived growth factor receptor alpha (Pdgfra) a
29 in-like growth factor binding protein 3, and platelet-derived growth factor receptor alpha (PDGFRA) i
30 opy number imbalances previously showed that platelet-derived growth factor receptor alpha (PDGFRA) i
31 stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor alpha (PDGFRA) k
32 ctivating stem cell factor receptor (Kit) or platelet-derived growth factor receptor alpha (Pdgfra) m
33 s (GIST) in pediatric patients harbor KIT or platelet-derived growth factor receptor alpha (PDGFRA) m
34 -oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) m
36 nd constitutively active forms of the KIT or platelet-derived growth factor receptor alpha (PDGFRA) r
37 caused by activating mutations of the KIT or platelet-derived growth factor receptor alpha (PDGFRA) t
38 errations in FLT3, tyrosine kinase 2 (TYK2), platelet-derived growth factor receptor alpha (PDGFRA),
43 ellular origin of new myelin by fate mapping platelet-derived growth factor receptor alpha (PDGFRalph
44 ase in hepatocyte proliferation secondary to platelet-derived growth factor receptor alpha (PDGFRalph
47 markers of oligodendrocytes, such as SOX10, platelet-derived growth factor receptor alpha (PDGFRalph
49 a poor prognosis and exhibit an increase in platelet-derived growth factor receptor alpha (PDGFRalph
51 lation of fetal thymic mesenchyme defined by platelet-derived growth factor receptor alpha (PDGFRalph
52 f epidermal growth factor receptor (EGFR) or platelet-derived growth factor receptor alpha (PDGFRalph
53 is, we have previously identified a role for platelet-derived growth factor receptor alpha (PDGFRalph
55 that TAg expression reduces the abundance of platelet-derived growth factor receptor alpha (PDGFRalph
58 many different signaling pathways, including platelet-derived growth factor receptor alpha (PDGFRalph
61 g a single variable domain antibody to mouse platelet-derived growth factor receptor alpha and a conv
62 ssed in primitive stromal cells that express platelet-derived growth factor receptor alpha and Sca-1
63 2 that lead to fusion of the FIP1-like 1 and platelet-derived growth factor receptor alpha genes, wit
64 The KIT protooncogene or, less frequently, platelet-derived growth factor receptor alpha is mutated
65 process, are similar to defects observed in platelet-derived growth factor receptor alpha null (PDGF
67 SMCs), interstitial cells of Cajal (ICC) and platelet-derived growth factor receptor alpha positive (
69 cule that inhibits activation of the KIT and platelet-derived growth factor receptor alpha proteins,
70 caused by activating mutations in the KIT or platelet-derived growth factor receptor alpha receptor t
71 l cord contain glial precursors that express platelet-derived growth factor receptor alpha subunit (P
72 more, oncogenic RAB35 is sufficient to drive platelet-derived growth factor receptor alpha to LAMP2-p
73 ating with an increase in Il-6 expression in platelet-derived growth factor receptor alpha(+) mesench
74 differentiated alpha-smooth muscle actin(+)/platelet-derived growth factor receptor alpha(+)/CD44(+)
75 racterized by activating mutations of KIT or platelet-derived growth factor receptor alpha(PDGFRA), w
76 roblast growth factor receptors 1 through 4, platelet-derived growth factor receptor alpha, RET, and
77 required event in two assays of PVR (namely, platelet-derived growth factor receptor alpha-mediated c
78 atrix by increasing nonmuscle myosin II- and platelet-derived growth factor receptor alpha-mediated c
79 n these KIT mutant cell lines and in KIT and platelet-derived growth factor receptor alpha-mutant GIS
80 ntramuscular interstitial cells of Cajal and platelet-derived growth factor receptor alpha-positive c
86 press the mesenchymal stem cell (MSC) marker platelet-derived growth factor receptor alpha; hence, we
87 cluding BCR-ABL, the C-KIT receptor, and the platelet-derived growth factor receptors alpha and beta,
88 has also been shown to inhibit KIT, ARG, and platelet-derived growth factor receptors alpha and beta,
90 of this Akt activation is dependent on alpha-platelet-derived growth factor receptor (alpha-PDGFR) si
91 lial cells and interstitial cells expressing platelet-derived growth factor receptor, alpha polypepti
92 ha(12) involves the receptor tyrosine kinase platelet derived growth factor receptor-alpha (PDGFRalph
93 In addition, both TGF-beta and Cbl regulated platelet-derived growth factor receptor-alpha (PDGFR alp
95 xpressing cells, nestin-expressing cells and platelet-derived growth factor receptor-alpha (PDGFR-alp
97 which results in a constitutively activated platelet-derived growth factor receptor-alpha (PDGFRA),
98 progenitors expressing a mesodermal marker, platelet-derived growth factor receptor-alpha (PDGFRA),
100 phosphatidylinositol 3-kinase (PI3K) mediate platelet-derived growth factor receptor-alpha (PDGFRalph
101 ell lines revealed co-activation of HER2 and platelet-derived growth factor receptor-alpha (PDGFRalph
102 opulation (SP) phenotype, PECAM-1 (CD31) and platelet-derived growth factor receptor-alpha (PDGFRalph
103 could be identified with antibodies against platelet-derived growth factor receptor-alpha (PDGFRalph
104 and flow sorted to isolate cells expressing platelet-derived growth factor receptor-alpha and exclud
105 ssion pattern, manifest in downregulation of platelet-derived growth factor receptor-alpha and recipr
106 d the oligodendrocyte precursor cell antigen platelet-derived growth factor receptor-alpha but did no
107 rom an interstitial deletion, that fuses the platelet-derived growth factor receptor-alpha gene (PDGF
108 ancer, and (ii) a frameshift mutation in the platelet-derived growth factor receptor-alpha gene.
109 to stabilize detrusor excitability involving platelet-derived growth factor receptor-alpha positive (
110 ultiple components of the Sonic hedgehog and platelet-derived growth factor receptor-alpha signal tra
111 s platelet-derived growth factor and soluble platelet-derived growth factor receptor-alpha were chara
112 atment led to downregulation of PDGFR-alpha (platelet-derived growth factor receptor-alpha) and Ki-67
113 ild-type or constitutively activated PDGFRA (platelet-derived growth factor receptor-alpha) under con
114 tyrosine kinases (RTKs) such as PDGFRalpha (platelet-derived growth factor receptor-alpha), which sh
115 al receptor tyrosine kinases, including KIT, platelet-derived growth factor receptor-alpha, and BCR-A
118 alpha signaling was conditionally blocked in platelet-derived growth factor receptor-alpha-positive a
119 y, 2) connective tissue progenitor cells, 3) platelet-derived growth factor receptor-alpha-positive c
122 N, resulting in increased phosphorylation of platelet-derived growth factor receptor and activation o
123 because of the overexpression/activation of platelet-derived growth factor receptor and ErbB2/3, inc
124 horylation of the receptor tyrosine kinases, platelet-derived growth factor receptor and HER3, or ove
126 y, we found that cross-communication between platelet-derived growth factor receptor and S1P(2) serve
127 factor tyrosine kinase receptors such as the platelet-derived growth factor receptor and the epiderma
128 sults in differential signalling by both the platelet-derived growth factor receptor and vascular end
129 vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or ep
130 CR-ABL1(+) leukemias and inhibitor of c-Abl, platelet-derived growth factor receptor, and c-Kit, decr
131 oral angiogenesis inhibitor targeting VEGFR, platelet-derived growth factor receptor, and c-kit.
132 ced RNA of epidermal growth factor receptor, platelet-derived growth factor receptor, and c-Met.
133 ion markers (alpha smooth muscle actin, beta platelet-derived growth factor receptor, and collagen I)
134 ing EGFR, vascular endothelial growth factor/platelet-derived growth factor receptor, and mTOR signal
135 st fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor, and other recep
136 ascular endothelial growth factor receptors, platelet-derived growth factor receptor, and RET tyrosin
137 thelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and stem-cell f
140 thelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combin
141 factor receptor, heat shock protein 90, and platelet-derived growth factor receptor as well as mutua
143 ling and functional screening identified the platelet-derived growth factor receptor b (PDGFRb) as bo
144 ranscriptional response to Mucorales reveals platelet-derived growth factor receptor B (PDGFRB) signa
145 oma cells, including increased expression of platelet derived growth factor receptor beta (PDGFRB) me
146 ent of known imatinib targets including Abl, platelet derived growth factor receptor beta (PDGFRbeta)
147 esenchymal cells give rise to adult CD73(+), platelet derived growth factor receptor beta(+), smooth
148 ociated astrocytes expressing phosphorylated platelet-derived growth factor receptor beta (at tyrosin
149 ligands of select receptor tyrosine kinases, platelet-derived growth factor receptor beta (PDGFR beta
151 To understand the mechanisms controlling platelet-derived growth factor receptor beta (PDGFR-beta
152 ression and ligand-independent activation of platelet-derived growth factor receptor beta (Pdgfr-beta
153 n profiling, which revealed up-regulation of platelet-derived growth factor receptor beta (Pdgfrb) an
154 germline mutation c.1681C>T (p.Arg561Cys) in platelet-derived growth factor receptor beta (PDGFRB) in
155 translocation partner was the gene encoding platelet-derived growth factor receptor beta (PdgfRbeta)
156 ntial role in blocking signals stemming from platelet-derived growth factor receptor beta (Pdgfrbeta)
157 E)B-RAF but rather is caused by upregulating platelet-derived growth factor receptor beta (PDGFRbeta)
159 es with reduction in the expression level of platelet-derived growth factor receptor beta (PDGFRbeta)
160 Analyses in vitro and in vivo showed that platelet-derived growth factor receptor beta (PDGFRbeta)
162 protein Sestrin 2 (Sesn2) as a suppressor of platelet-derived growth factor receptor beta (Pdgfrbeta)
163 MEFs show slower kinetics of ligand-induced platelet-derived growth factor receptor beta (PDGFRbeta)
164 he overexpression and excessive signaling of platelet-derived growth factor receptor beta (PDGFRbeta)
166 hat imatinib, a tyrosine kinase inhibitor of platelet-derived growth factor receptor beta (PDGFRbeta)
167 (dimethylamino)benzylidenyl]indolin-2-one (a platelet-derived growth factor receptor beta and a fibro
168 Gint4.T aptamer specifically recognizes platelet-derived growth factor receptor beta and can cro
169 ponse to the cooperative signal generated by platelet-derived growth factor receptor beta and integri
170 class III receptor tyrosine kinases such as platelet-derived growth factor receptor beta and VEGF re
172 in 2 (IGFBP-2), nerve growth factor (b-NGF), platelet-derived growth factor receptor beta polypeptide
173 erved in a laser-induced model of CNV that a platelet-derived growth factor receptor beta positive (P
175 gnificantly more NIK(+) ECs and perivascular platelet-derived growth factor receptor beta(+) preFDCs,
176 cytes and immunoreactivity for desmin, NG-2, platelet-derived growth factor receptor beta, and the la
177 ional inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor beta, and Tie-2.
178 pericytic markers, including CD146, NG2, and platelet-derived growth factor receptor beta, but not th
179 g., expression of alpha smooth muscle actin, platelet-derived growth factor receptor beta, desmin, vi
180 l cell markers smooth muscle alpha-actin and platelet-derived growth factor receptor beta, epidermal
181 the extracellular ligand-binding domains of platelet-derived growth factor receptor beta, epidermal
184 e first PDZ domain of NHERF is known to bind platelet-derived growth factor-receptor beta (PDGF-Rbeta
185 rs of Colalpha1 (I), Colalpha2 (I), and beta-platelet-derived growth factor receptor (beta-Pdgfr) wit
186 asing evidence indicates the significance of platelet-derived growth factor receptor-beta (beta-PDGFR
188 elial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor-beta (PDGFR-beta
189 rived growth factor B (PDGF-B) retention and platelet-derived growth factor receptor-beta (PDGFR-beta
191 f the tumor stroma-reactive STI571, a potent platelet-derived growth factor receptor-beta (PDGFr-beta
192 nd dendritic spine formation through Rabex-5/platelet-derived growth factor receptor-beta (PDGFRbeta)
194 igration are substantially controlled by the platelet-derived growth factor receptor-beta (PDGFRbeta)
195 or kinase-2 (GRK2) serine-phosphorylates the platelet-derived growth factor receptor-beta (PDGFRbeta)
196 resistant (UM-UC13) cell lines revealed that platelet-derived growth factor receptor-beta (PDGFRbeta)
197 (GRK2) can phosphorylate and desensitize the platelet-derived growth factor receptor-beta (PDGFRbeta)
199 led that among known sunitinib targets, only platelet-derived growth factor receptor-beta and vascula
201 y arterial muscularization via inhibition of platelet-derived growth factor receptor-beta on vascular
202 al adhesion kinase and SHP2; 3) it modulated platelet-derived growth factor receptor-beta signaling;
204 a significant decrease in the expression of platelet-derived growth factor receptor-beta, a tyrosine
205 Gli2) are expressed exclusively in adjacent platelet-derived growth factor receptor-beta-positive in
207 gets, including beta(2)-adrenergic receptor, platelet-derived growth factor receptor, cystic fibrosis
208 structure provides a first glimpse into how platelet-derived growth factor receptor ECD, upon ligand
211 dothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor families of RTKs
213 phosphorylated proangiogenic RTKs, including platelet-derived growth factor receptor, fibroblast grow
214 ne kinases involved in angiogenesis, such as platelet-derived growth factor receptor, fibroblast grow
215 IPSCs via the following cascade: D2-->G(i)-->platelet-derived growth factor receptor--> increase phos
216 or of vascular endothelial growth factor and platelet-derived growth factor receptors, had only 4% as
217 th factor receptor-2 (IC(50) = 0.21 microM), platelet-derived growth factor receptor (IC(50) = 0.36 m
218 ns such as epidermal growth factor receptor, platelet-derived growth factor receptor, IGFR1, and c-Me
219 vec), an inhibitor of phosphorylation of the platelet-derived growth factor receptor, in combination
220 structure of PDGFRbeta [a full-length human platelet-derived growth factor receptor], in complex wit
221 lating migration was inhibited by a specific platelet-derived growth factor receptor inhibitor (AG129
222 vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibitor PTK787
223 he vascular endothelial growth factor (VEGF)/platelet-derived growth factor receptor inhibitor suniti
224 and maximum-tolerated dose (MTD) of an oral platelet-derived growth factor receptor inhibitor, CP-86
225 ntibody or with small molecule inhibitors of platelet-derived growth factor receptor kinase or downst
226 st fibroblast growth factor receptor kinase, platelet-derived growth factor receptor kinase, and glyc
227 actions, and novel cartilage proteins CD109, platelet-derived growth factor receptor-like, angiopoiet
228 targeting stem cell factor receptor (C-KIT), platelet-derived growth factor receptor, mammalian targe
229 receptors (epidermal growth factor receptor, platelet-derived growth factor receptor, MET and ERBB2),
230 c-kit, epidermal growth factor receptor, and platelet-derived growth factor receptor on malignant end
232 razin-2(1H)-ones toward potent and effective platelet-derived growth factor receptor (PDGF-R) beta-in
233 ein kinase D (PKD) mediates signals from the platelet-derived growth factor receptor (PDGF-R) to cont
234 n colon carcinoma express high levels of the platelet-derived growth factor receptor (PDGF-R), wherea
235 cells were selected using a surface marker, platelet derived growth factor receptor (PDGFR) alpha.
236 tion between growth factor receptors such as platelet derived growth factor receptor (PDGFR) and inte
238 an forebrain cells for CD140a, an epitope of platelet derived growth factor receptor (PDGFR)alpha, wh
239 gase for ubiquitinylation and degradation of platelet-derived growth factor receptor (PDGFR) alpha an
240 viously, we had shown that disruption of the platelet-derived growth factor receptor (PDGFR) alpha in
242 ng fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and inte
243 nimals to determine the relationship between platelet-derived growth factor receptor (PDGFR) and sero
245 st growth factor receptor (FGFR) family, the platelet-derived growth factor receptor (PDGFR) family,
246 dothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases
247 dothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases.
248 othelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) modulate
249 the other, tyrphostin A9 (A9), inhibits the platelet-derived growth factor receptor (PDGFR) pathway.
252 s were analyzed for molecules within the KIT/platelet-derived growth factor receptor (PDGFR) signal t
253 at these compounds act through inhibition of platelet-derived growth factor receptor (PDGFR) signalin
257 c-ABL, Janus-activated kinase 2 (JAK2), and platelet-derived growth factor receptor (PDGFR) that gen
258 epidermal growth factor receptor (EGFR), the platelet-derived growth factor receptor (PDGFR), and Erb
259 kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT
260 NHERFs were shown to interact directly with platelet-derived growth factor receptor (PDGFR), and we
261 dothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), FLT3, R
262 marginal efficacy whereas a soluble form of platelet-derived growth factor receptor (PDGFR), PDGFRbe
263 sitol 3-kinase (PI3K) and the potent mitogen platelet-derived growth factor receptor (PDGFR), thereby
264 YR mice had significantly reduced amounts of platelet-derived growth factor receptor (PDGFR), which i
265 cancer-associated kinases, including KIT and platelet-derived growth factor receptor (PDGFR), with br
266 atic endothelial cells and signaling through platelet-derived growth factor receptor (PDGFR)-beta in
267 tor receptor-beta blockade in vivo using the platelet-derived growth factor receptor (PDGFR)-beta inh
268 platelet-derived growth factor BB (PDGF-BB)/platelet-derived growth factor receptor (PDGFR)-beta sig
269 isib also inhibited ALL proliferation in ABL/platelet-derived growth factor receptor (PDGFR)-mutant m
272 l stromal tumor (GIST) cells overexpress the platelet-derived growth factor receptor (PDGFR)A, althou
274 Anterograde transport mutants display low platelet-derived growth factor receptor (PDGFR)alpha lev
275 inases for growth and/or survival, including platelet-derived growth factor receptor (PDGFR)alpha, ME
276 othelial growth factor receptor (VEGFR)2 and platelet-derived growth factor receptor (PDGFR)alpha.
280 inhibition of the Abelson kinase (c-Abl) and platelet-derived growth factor receptors (PDGFR) in expe
281 endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], Flt3, a
282 yrosine kinase inhibitor that targets c-Kit, platelet-derived growth factor receptors (PDGFRs) and c-
284 ne kinase activity of ABL1/BCR-ABL1 and KIT, platelet-derived growth factor receptors (PDGFRs), and t
285 e provide evidence that VEGF-A can stimulate platelet-derived growth factor receptors (PDGFRs), there
287 Our results identify the Snail-PTEN platelet-derived growth factor receptor/phosphatidylinos
288 Pathway analysis identified dysregulated platelet-derived growth factor receptor signaling in BPC
289 endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell facto
290 itor, has activity against VEGFRs as well as platelet-derived growth factor receptors, stem-cell fact
292 GFR-1/Flt-1, VEGFR-2/KDR, VEGFR-3/Flt-4, the platelet-derived growth factor receptor tyrosine kinase,
293 xpression of cell surface proteins including platelet-derived growth factor receptor, vascular cell a
294 s multiple receptor tyrosine kinases such as platelet-derived growth factor receptor, vascular endoth
296 mens and orthotopic tumors revealed that the platelet-derived growth factor receptor was expressed on
298 m for high avidity binding to phosphorylated platelet-derived growth factor receptors, which would re
300 w here that in PC-3MM2 tumors, inhibition of platelet-derived growth factor receptor with imatinib re
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。